Registration Statement Related To Cleveland BioLabs-Cytocom Merger Declared Effective By SEC

Cleveland BioLabs Inc (NASDAQ:CBLI) says that the SEC registration statement regarding the previously announced merger with Cytocom Inc was declared effective by the SEC on June 10.
The merger is expected to close in the Q3 of 2021, subject to approval by Cleveland BioLabs' stockholders.
A special meeting of the Cleveland BioLabs stockholders related to the merger will be held virtually on July 6 at 10:00 a.m. E.T.
After the deal's closure, the new combined company will be named Cytocom Inc, and its common stock will trade on NASDAQ under the symbol "CYTO."
The deal was initially announced in October last year, and the registration document was filed in February.
Price Action: CBLI shares are up 8.66% at $5.27 during the premarket trading session on the last check Friday.

To add Benzinga News as your preferred source on Google, click here.

Cleveland BioLabs Inc (NASDAQ:CBLI) says that the SEC registration statement regarding the previously announced merger with Cytocom Inc was declared effective by the SEC on June 10.
The merger is expected to close in the Q3 of 2021, subject to approval by Cleveland BioLabs' stockholders.
A special meeting of the Cleveland BioLabs stockholders related to the merger will be held virtually on July 6 at 10:00 a.m. E.T.
After the deal's closure, the new combined company will be named Cytocom Inc, and its common stock will trade on NASDAQ under the symbol "CYTO."
The deal was initially announced in October last year, and the registration document was filed in February.
Price Action: CBLI shares are up 8.66% at $5.27 during the premarket trading session on the last check Friday.

To add Benzinga News as your preferred source on Google, click here.